---
title: "Pre-market hot trades in US stocks: Inspire Medical pre-market down 21.37%; Flora Growth pre-market up 14.86%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270163641.md"
description: "Inspire Medical pre-market down 21.37%; Flora Growth pre-market up 14.86%; Athira Pharma pre-market up 61.30%; Sable Offshore pre-market up 45.83%; Urban-Gro pre-market up 33.07%"
datetime: "2025-12-18T13:07:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270163641.md)
  - [en](https://longbridge.com/en/news/270163641.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270163641.md)
generator: "portal-rs"
---

# Pre-market hot trades in US stocks: Inspire Medical pre-market down 21.37%; Flora Growth pre-market up 14.86%

**Hot Trades in Pre-Market US Stocks**

Inspire Medical fell 21.37% in pre-market trading. There have been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news

Flora Growth rose 14.86% in pre-market trading, with no significant news recently. Trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

**Top Gainers in Pre-Market US Stocks**

Athira Pharma rose 61.30% in pre-market trading. Based on recent key news:

1.  On December 18, Athira Pharma submitted an 8-K filing to the SEC, indicating significant progress for the company. This filing is typically used to disclose important events or changes within the company, which may involve updates on financial or operational aspects, leading to a substantial increase in stock price.

2.  There have been no other significant news recently. The biotechnology sector has been quite volatile lately.

Sable Offshore rose 45.83% in pre-market trading. Based on recent news:

1.  On December 17, Sable Offshore received confirmation from PHMSA that its pipeline has been classified as an interstate facility. This reclassification shifts regulatory oversight to PHMSA, with the pipeline connecting the Santa Ynez Unit and Pentland Station. PHMSA's review includes on-site inspections and records, and the pipeline is considered "active" under PHMSA regulations. This news boosted market confidence and drove the stock price up.

2.  On December 18, Roth MKM analyst Leo Mariani maintained a buy rating on Sable Offshore and set a target price of $22. Mariani is a five-star analyst in the energy sector, with an average return rate of 24.9% and a success rate of 58.96%. The analyst's positive rating further enhanced investor confidence, driving the stock price up.

3.  On December 18, Sable Offshore's Las Flores pipeline system was deemed "active" by PHMSA. This pipeline has been regulated by OSFM since 2016 and will be overseen by PHMSA after reclassification. This regulatory transition is viewed positively by the market, further driving the stock price up. The energy sector has performed strongly recently, and regulatory changes have had a positive impact.

Urban-Gro rose 33.07% in pre-market trading, with no significant news recently. Trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation

### Related Stocks

- [INSP.US](https://longbridge.com/en/quote/INSP.US.md)
- [FLGC.US](https://longbridge.com/en/quote/FLGC.US.md)
- [ZSTK.US](https://longbridge.com/en/quote/ZSTK.US.md)

## Related News & Research

- [Inspire Medical Systems (INSP) Stock Trades Below Fair Value As Caution Lingers](https://longbridge.com/en/news/296100205.md)
- [ZeroStack shares jump after $1 billion MemeCore token deal](https://longbridge.com/en/news/296387576.md)
- [Inspire Medical Systems, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next](https://longbridge.com/en/news/295118552.md)
- [Inspire Medical Systems (NYSE:INSP) Issues Earnings Results, Beats Expectations By $0.38 EPS](https://longbridge.com/en/news/294734486.md)
- [Inspire Medical Q2 revenue falls less than expected](https://longbridge.com/en/news/294732534.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**